

Interview Summary	Application No.	Applicant(s)	
	10/054,611	CECH ET AL.	
	Examiner	Art Unit	
	Malgorzata A. Walicka	1652	

All participants (applicant, applicant's representative, PTO personnel):

(1) Malgorzata A. Walicka.

(3) J. Michael Schiff.

(2) Rebecca Prouty.

(4) _____.

Date of Interview: 02 September 2004.

Type: a) ☐ Telephonic b) ☐ Video Conference
c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☒ Yes e) ☐ No.

If Yes, brief description: Linger et al, Science, 267, 561-567, 1997 and nucleotide sequence AA28196.

Claim(s) discussed: 1-19, 21 and 35-46.

Identification of prior art discussed: Linger et al, Science, 267, 561-567, 1997 and nucleotide sequence AA28196.


Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Discussed applicants amended claims. Examiner suggested some additional amendments as follows: preamble to claim 1 and 13 should be amended to indicate the function of the nucleic acid should be identified as encoding hTERT or fragment thereof. Claims 2 and 14 should be amended to include step c) as in claim 1. Claims 5-9 should be amended to change the language "comprises" to "consists essentially of". Claim 13 should indicate in part c) the function of nucleic acid as encoding hTERT or fragment thereof. Amendments to claims 39-40 and 45-46 were discussed. Discussed the potential applicability of Linger et al (Science , 276, 561-567, 1997) and nucleotide sequence AA2196 to an art rejection. .